ANGLE Secures FDA Clearance for Parsortix, Set to Revolutionize Cancer Detection

September 23, 2024 03:34 AM PDT | By Team Kalkine Media

ANGLE Secures FDA Clearance for Parsortix, Set to Revolutionize Cancer Detection — Image source: Shutterstock

Strategic Partnership with NuProbe USA

ANGLE recently announced a significant partnership with NuProbe USA, aimed at accelerating the development of a groundbreaking "pan-cancer" molecular sequencing assay. This innovative test is designed to integrate seamlessly with ANGLE's Parsortix liquid biopsy system, enabling it to be utilized across various cancer types.

The collaboration will leverage both technologies to allow for the analysis of circulating tumour cell DNA (CTC-DNA) as well as a combined analysis of circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) from a single blood sample. This dual approach is expected to offer a comprehensive overview of a cancer's genetic profile, potentially enhancing diagnosis and treatment options.

Collaboration with Recursion Pharmaceuticals

In addition to its partnership with NuProbe, ANGLE has secured an agreement with Nasdaq-listed Recursion Pharmaceuticals Inc. This collaboration will involve a fully funded pilot study, as Recursion focuses on utilizing artificial intelligence and automation for experimental biology and cellular disease model testing. This partnership signifies ANGLE's commitment to innovative research and development in cancer diagnostics.

Progress and Recognition

ANGLE has recently published data supporting the FDA approval of its Parsortix PC1 system for harvesting circulating tumour cells, with findings appearing in the Journal of Experimental & Clinical Cancer Research. This recognition highlights the rigorous scientific foundation upon which ANGLE's technologies are built.

Andrew Newland, the CEO of ANGLE, and his team have successfully developed a unique cancer diagnostic technology, positioning the company on the brink of commercial success. A recent fundraising initiative raised £9.3 million, which is anticipated to facilitate the company’s progression towards cash flow break-even by the end of next year.

ANGLE PLC is at the forefront of innovation in cancer diagnostics, with its advanced liquid biopsy technology and strategic partnerships poised to enhance patient outcomes. As the company continues to develop its capabilities in molecular analysis, it remains a significant player in the evolving landscape of cancer treatment and diagnosis.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.